कैंसर निदान जर्नल

अमूर्त

Transrectal Ultrasound-Guided Prostate Biopsy: A Minimally Invasive Diagnostic Procedure for Prostate Cancer Detection

David Chaoxin

Prostate cancer is one of the most prevalent malignancies affecting men worldwide. Early detection and accurate diagnosis are paramount for successful treatment outcomes. Transrectal ultrasound (TRUS)-guided prostate biopsy has emerged as a pivotal diagnostic tool in the assessment of prostate cancer. This abstract provides a concise overview of the procedure, its indications, techniques, and key considerations. TRUS involves the insertion of a specialized ultrasound probe into the rectum to visualize the prostate gland in real-time. This imaging modality enables urologists to identify suspicious areas within the prostate, which may harbor cancerous tissue. When suspicious regions are identified, TRUS can guide the precise placement of biopsy needles for tissue sampling. This targeted approach enhances the accuracy of prostate cancer diagnosis compared to blind biopsies. In addition to its diagnostic benefits, TRUS offers advantages such as minimal invasiveness and a relatively low risk of complications. This abstract explores the patient selection criteria, preparation, and potential risks associated with TRUS-guided prostate biopsy. Furthermore, this abstract briefly discusses the importance of histopathological analysis in confirming the presence of prostate cancer and determining its aggressiveness. The integration of TRUS with advanced imaging techniques and biomarker assessment has further improved the accuracy of prostate cancer diagnosis. In conclusion, transrectal ultrasound-guided prostate biopsy is a valuable tool in the diagnosis and risk stratification of prostate cancer. It offers a minimally invasive approach to obtaining tissue samples, aiding in the timely and precise identification of this prevalent malignancy. An understanding of the procedural nuances and considerations is essential for healthcare professionals involved in the management of prostate cancer.